vs

Side-by-side financial comparison of LINKBANCORP, Inc. (LNKB) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.

RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $46.0M, roughly 1.2× LINKBANCORP, Inc.). LINKBANCORP, Inc. runs the higher net margin — 6.4% vs -83.0%, a 89.4% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 7.3%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 6.6%).

LINKBANCORP, Inc. is a US-based bank holding company that offers comprehensive retail and commercial banking services to individual consumers, small businesses, and mid-sized enterprises. Its core offerings include deposit accounts, lending products, wealth management solutions, and digital banking services, primarily serving customers across regional markets in Pennsylvania.

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

LNKB vs RYTM — Head-to-Head

Bigger by revenue
RYTM
RYTM
1.2× larger
RYTM
$57.3M
$46.0M
LNKB
Growing faster (revenue YoY)
RYTM
RYTM
+29.6% gap
RYTM
36.9%
7.3%
LNKB
Higher net margin
LNKB
LNKB
89.4% more per $
LNKB
6.4%
-83.0%
RYTM
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
48.5%
6.6%
LNKB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LNKB
LNKB
RYTM
RYTM
Revenue
$46.0M
$57.3M
Net Profit
$2.9M
$-47.5M
Gross Margin
91.6%
Operating Margin
8.5%
-82.2%
Net Margin
6.4%
-83.0%
Revenue YoY
7.3%
36.9%
Net Profit YoY
-61.2%
-9.6%
EPS (diluted)
$0.08
$-0.73

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LNKB
LNKB
RYTM
RYTM
Q4 25
$46.0M
$57.3M
Q3 25
$44.8M
$51.3M
Q2 25
$42.3M
$48.5M
Q1 25
$53.4M
$32.7M
Q4 24
$42.9M
$41.8M
Q3 24
$42.9M
$33.3M
Q2 24
$41.3M
$29.1M
Q1 24
$40.5M
$26.0M
Net Profit
LNKB
LNKB
RYTM
RYTM
Q4 25
$2.9M
$-47.5M
Q3 25
$7.8M
$-52.9M
Q2 25
$7.4M
$-46.6M
Q1 25
$15.3M
$-49.5M
Q4 24
$7.6M
$-43.3M
Q3 24
$7.1M
$-43.6M
Q2 24
$5.8M
$-32.3M
Q1 24
$5.7M
$-141.4M
Gross Margin
LNKB
LNKB
RYTM
RYTM
Q4 25
91.6%
Q3 25
89.3%
Q2 25
88.6%
Q1 25
88.8%
Q4 24
90.9%
Q3 24
88.5%
Q2 24
89.9%
Q1 24
89.2%
Operating Margin
LNKB
LNKB
RYTM
RYTM
Q4 25
8.5%
-82.2%
Q3 25
22.3%
-102.6%
Q2 25
22.4%
-93.4%
Q1 25
36.0%
-143.7%
Q4 24
22.6%
-98.6%
Q3 24
21.3%
-132.0%
Q2 24
18.0%
-139.2%
Q1 24
18.1%
-538.7%
Net Margin
LNKB
LNKB
RYTM
RYTM
Q4 25
6.4%
-83.0%
Q3 25
17.5%
-103.1%
Q2 25
17.5%
-96.1%
Q1 25
28.7%
-151.4%
Q4 24
17.7%
-103.6%
Q3 24
16.5%
-131.2%
Q2 24
14.1%
-110.9%
Q1 24
14.1%
-544.4%
EPS (diluted)
LNKB
LNKB
RYTM
RYTM
Q4 25
$0.08
$-0.73
Q3 25
$0.21
$-0.82
Q2 25
$0.20
$-0.75
Q1 25
$0.41
$-0.81
Q4 24
$0.21
$-0.71
Q3 24
$0.19
$-0.73
Q2 24
$0.16
$-0.55
Q1 24
$0.15
$-2.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LNKB
LNKB
RYTM
RYTM
Cash + ST InvestmentsLiquidity on hand
$52.3M
$388.9M
Total DebtLower is stronger
$177.3M
Stockholders' EquityBook value
$306.4M
$139.1M
Total Assets
$3.1B
$480.2M
Debt / EquityLower = less leverage
0.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LNKB
LNKB
RYTM
RYTM
Q4 25
$52.3M
$388.9M
Q3 25
$194.2M
$416.1M
Q2 25
$155.1M
$291.0M
Q1 25
$220.2M
$314.5M
Q4 24
$166.1M
$320.6M
Q3 24
$191.2M
$298.4M
Q2 24
$181.7M
$319.1M
Q1 24
$172.3M
$201.2M
Total Debt
LNKB
LNKB
RYTM
RYTM
Q4 25
$177.3M
Q3 25
$102.3M
Q2 25
$102.3M
Q1 25
$102.7M
Q4 24
$112.5M
Q3 24
$102.4M
Q2 24
$102.3M
Q1 24
$102.2M
Stockholders' Equity
LNKB
LNKB
RYTM
RYTM
Q4 25
$306.4M
$139.1M
Q3 25
$305.5M
$148.8M
Q2 25
$298.0M
$-11.9M
Q1 25
$294.1M
$18.9M
Q4 24
$280.2M
$21.7M
Q3 24
$277.4M
$11.2M
Q2 24
$271.4M
$39.3M
Q1 24
$268.2M
$61.6M
Total Assets
LNKB
LNKB
RYTM
RYTM
Q4 25
$3.1B
$480.2M
Q3 25
$3.1B
$506.9M
Q2 25
$2.9B
$372.7M
Q1 25
$2.9B
$386.7M
Q4 24
$2.9B
$392.3M
Q3 24
$2.9B
$363.6M
Q2 24
$2.9B
$381.8M
Q1 24
$2.8B
$258.7M
Debt / Equity
LNKB
LNKB
RYTM
RYTM
Q4 25
0.58×
Q3 25
0.33×
Q2 25
0.34×
Q1 25
0.35×
Q4 24
0.40×
Q3 24
0.37×
Q2 24
0.38×
Q1 24
0.38×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LNKB
LNKB
RYTM
RYTM
Operating Cash FlowLast quarter
$25.3M
$-25.4M
Free Cash FlowOCF − Capex
$23.8M
FCF MarginFCF / Revenue
51.7%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
8.59×
TTM Free Cash FlowTrailing 4 quarters
$55.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LNKB
LNKB
RYTM
RYTM
Q4 25
$25.3M
$-25.4M
Q3 25
$23.6M
$-26.6M
Q2 25
$6.3M
$-23.3M
Q1 25
$2.6M
$-40.4M
Q4 24
$25.4M
$-18.8M
Q3 24
$14.0M
$-25.2M
Q2 24
$6.4M
$-29.1M
Q1 24
$-771.0K
$-40.7M
Free Cash Flow
LNKB
LNKB
RYTM
RYTM
Q4 25
$23.8M
Q3 25
$23.2M
Q2 25
$6.1M
Q1 25
$2.2M
Q4 24
$22.6M
Q3 24
$13.1M
Q2 24
$6.3M
Q1 24
$-1.2M
FCF Margin
LNKB
LNKB
RYTM
RYTM
Q4 25
51.7%
Q3 25
51.8%
Q2 25
14.5%
Q1 25
4.2%
Q4 24
52.6%
Q3 24
30.5%
Q2 24
15.3%
Q1 24
-3.0%
Capex Intensity
LNKB
LNKB
RYTM
RYTM
Q4 25
3.2%
Q3 25
0.8%
Q2 25
0.4%
Q1 25
0.7%
Q4 24
6.7%
Q3 24
2.1%
Q2 24
0.1%
Q1 24
1.1%
Cash Conversion
LNKB
LNKB
RYTM
RYTM
Q4 25
8.59×
Q3 25
3.01×
Q2 25
0.85×
Q1 25
0.17×
Q4 24
3.35×
Q3 24
1.97×
Q2 24
1.10×
Q1 24
-0.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons